Teicoplanin shortage — DE supply status & alternatives

Teicoplanin

—

🇦🇺 AUST R 389256 · Medicianz Healthcare Pty Ltd

In shortage · Australia

Teicoplanin Eberth

In declared shortage · 🇦🇺 Australia & also short in🇩🇪 DE

Critical shortage

Product discontinued / no longer available on the Australian market.

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Teicoplanin
Brand names	Teicoplanin Eberth

Controlled substance	No

Marketing-authorisation holders	Medicianz Healthcare Pty Ltd, SANDOZ LIMITED, HAMELN PHARMA LTD, Generics (UK) Limited +4 more

Registrations on file	17

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Other markets

🇮🇹 IT

€41.61

Retail price

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Shortage status by regulator official notices

🇦🇺

Australia

TGA · 2h ago

High

🇩🇪

Germany

BfArM · 1d ago

High

Verified timeline regulator events

🇦🇺 31 Jan 2027

high reported

🇩🇪 18 Dec 2024

high reported

Sources official regulators

🇦🇺

TGA

verified 2h ago

verify ↗

🇩🇪

BfArM

verified 1d ago

verify ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders17 registrations · 8 MA holders

Product	Strength	Form	Market	MA holder	Status
Medicianz	400mg	—	🇦🇺 AU	Medicianz Healthcare Pty Ltd	Active
TEICOPLANIN 100 MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION/ INFUSION OR ORAL SOLUTION	100 MG	injection	🇬🇧 GB	SANDOZ LIMITED	Active
TEICOPLANIN 200 MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION/ INFUSION OR ORAL SOLUTION	200 MG	injection	🇬🇧 GB	SANDOZ LIMITED	Active
TEICOPLANIN 400 MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION/ INFUSION OR ORAL SOLUTION	400 MG	injection	🇬🇧 GB	SANDOZ LIMITED	Active
TEICOPLANIN 200 MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION/INFUSION OR ORAL SOLUTION	200 MG	injection	🇬🇧 GB	HAMELN PHARMA LTD	Active
TEICOPLANIN 400 MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION/INFUSION OR ORAL SOLUTION	400 MG	injection	🇬🇧 GB	HAMELN PHARMA LTD	Active
TEICOPLANIN 100 MG, POWDER FOR SOLUTION FOR INJECTION/INFUSION OR ORAL SOLUTION	100 MG	injection	🇬🇧 GB	Generics (UK) Limited	Active
TEICOPLANIN 200 MG, POWDER FOR SOLUTION FOR INJECTION/INFUSION OR ORAL SOLUTION	200 MG	injection	🇬🇧 GB	Generics (UK) Limited	Active
TEICOPLANIN 400 MG, POWDER FOR SOLUTION FOR INJECTION/INFUSION OR ORAL SOLUTION	400 MG	injection	🇬🇧 GB	Generics (UK) Limited	Active
TEICOPLANIN 200MG POWDER FOR SOLUTION FOR INJECTION/INFUSION OR ORAL SOLUTION	200MG	injection	🇬🇧 GB	ACS DOBFAR SPA	Active
TEICOPLANIN 400MG POWDER FOR SOLUTION FOR INJECTION/INFUSION OR ORAL SOLUTION	400MG	injection	🇬🇧 GB	ACS DOBFAR SPA	Active
TEICOPLANIN 200 MG POWDER FOR SOLUTION FOR INJECTION/INFUSION OR ORAL SOLUTION	200 MG	injection	🇬🇧 GB	HIKMA FARMACEUTICA (PORTUGAL) SA	Active
TEICOPLANIN 400 MG POWDER FOR SOLUTION FOR INJECTION/INFUSION OR ORAL SOLUTION	400 MG	injection	🇬🇧 GB	HIKMA FARMACEUTICA (PORTUGAL) SA	Active
Teicoplanin Seacross	200 MG	injection	🇬🇧 GB	SEACROSS PHARMACEUTICALS LIMITED	Active
Teicoplanin Seacross	400 MG	injection	🇬🇧 GB	SEACROSS PHARMACEUTICALS LIMITED	Active

+2 more registrations on file

Mederti Drug Report

Generated 1 July 2026 · Australia market · 2 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.